441 related articles for article (PubMed ID: 24876152)
21. Activation of the urokinase plasminogen activator/urokinase plasminogen activator receptor system and redistribution of E-cadherin are associated with hepatocyte growth factor-induced motility of pancreas tumor cells overexpressing Met.
Paciucci R; Vilá MR; Adell T; Díaz VM; Torà M; Nakamura T; Real FX
Am J Pathol; 1998 Jul; 153(1):201-12. PubMed ID: 9665481
[TBL] [Abstract][Full Text] [Related]
22. SB365, Pulsatilla saponin D, targets c-Met and exerts antiangiogenic and antitumor activities.
Hong SW; Jung KH; Lee HS; Son MK; Yan HH; Kang NS; Lee J; Hong SS
Carcinogenesis; 2013 Sep; 34(9):2156-69. PubMed ID: 23671132
[TBL] [Abstract][Full Text] [Related]
23. Expression of Ezrin, HGF, C-met in pancreatic cancer and non-cancerous pancreatic tissues of rats.
Tan XG; Yang ZL
Hepatobiliary Pancreat Dis Int; 2010 Dec; 9(6):639-44. PubMed ID: 21134835
[TBL] [Abstract][Full Text] [Related]
24. Growth factor-dependent activation of the MAPK pathway in human pancreatic cancer: MEK/ERK and p38 MAP kinase interaction in uPA synthesis.
Lee KH; Hyun MS; Kim JR
Clin Exp Metastasis; 2003; 20(6):499-505. PubMed ID: 14598883
[TBL] [Abstract][Full Text] [Related]
25. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer.
Maulik G; Kijima T; Ma PC; Ghosh SK; Lin J; Shapiro GI; Schaefer E; Tibaldi E; Johnson BE; Salgia R
Clin Cancer Res; 2002 Feb; 8(2):620-7. PubMed ID: 11839685
[TBL] [Abstract][Full Text] [Related]
26. Regulation of the urokinase-type plasminogen activator gene by the oncogene Tpr-Met involves GRB2.
Besser D; Bardelli A; Didichenko S; Thelen M; Comoglio PM; Ponzetto C; Nagamine Y
Oncogene; 1997 Feb; 14(6):705-11. PubMed ID: 9038378
[TBL] [Abstract][Full Text] [Related]
27. Growth inhibition and apoptosis in liver myofibroblasts promoted by hepatocyte growth factor leads to resolution from liver cirrhosis.
Kim WH; Matsumoto K; Bessho K; Nakamura T
Am J Pathol; 2005 Apr; 166(4):1017-28. PubMed ID: 15793283
[TBL] [Abstract][Full Text] [Related]
28. Suppression of urokinase plasminogen activator receptor inhibits proliferation and migration of pancreatic adenocarcinoma cells via regulation of ERK/p38 signaling.
Xue A; Xue M; Jackson C; Smith RC
Int J Biochem Cell Biol; 2009; 41(8-9):1731-8. PubMed ID: 19433314
[TBL] [Abstract][Full Text] [Related]
29. A selective c-met inhibitor blocks an autocrine hepatocyte growth factor growth loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells.
Hov H; Holt RU; Rø TB; Fagerli UM; Hjorth-Hansen H; Baykov V; Christensen JG; Waage A; Sundan A; Børset M
Clin Cancer Res; 2004 Oct; 10(19):6686-94. PubMed ID: 15475459
[TBL] [Abstract][Full Text] [Related]
30. Hepatocyte growth factor/c-Met signaling promotes the progression of experimental human neuroblastomas.
Hecht M; Papoutsi M; Tran HD; Wilting J; Schweigerer L
Cancer Res; 2004 Sep; 64(17):6109-18. PubMed ID: 15342394
[TBL] [Abstract][Full Text] [Related]
31. Targeting HGF/c-MET Axis in Pancreatic Cancer.
Pothula SP; Xu Z; Goldstein D; Pirola RC; Wilson JS; Apte MV
Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33271944
[TBL] [Abstract][Full Text] [Related]
32. Cancer cell-derived IL-1α promotes HGF secretion by stromal cells and enhances metastatic potential in pancreatic cancer cells.
Xu D; Matsuo Y; Ma J; Koide S; Ochi N; Yasuda A; Funahashi H; Okada Y; Takeyama H
J Surg Oncol; 2010 Oct; 102(5):469-77. PubMed ID: 20872950
[TBL] [Abstract][Full Text] [Related]
33. Cyclooxygenase-2-selective nonsteroidal anti-inflammatory drugs inhibit hepatocyte growth factor/scatter factor-induced angiogenesis.
Sengupta S; Sellers LA; Cindrova T; Skepper J; Gherardi E; Sasisekharan R; Fan TP
Cancer Res; 2003 Dec; 63(23):8351-9. PubMed ID: 14678996
[TBL] [Abstract][Full Text] [Related]
34. The scatter factor/hepatocyte growth factor: c-met pathway in human embryonal central nervous system tumor malignancy.
Li Y; Lal B; Kwon S; Fan X; Saldanha U; Reznik TE; Kuchner EB; Eberhart C; Laterra J; Abounader R
Cancer Res; 2005 Oct; 65(20):9355-62. PubMed ID: 16230398
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of growth, invasion, and metastasis of human pancreatic carcinoma cells by NK4 in an orthotopic mouse model.
Tomioka D; Maehara N; Kuba K; Mizumoto K; Tanaka M; Matsumoto K; Nakamura T
Cancer Res; 2001 Oct; 61(20):7518-24. PubMed ID: 11606388
[TBL] [Abstract][Full Text] [Related]
36. Epidermal growth factor and hepatocyte growth factor cooperate to enhance cell proliferation, scatter, and invasion in murine mammary epithelial cells.
Accornero P; Miretti S; Starvaggi Cucuzza L; Martignani E; Baratta M
J Mol Endocrinol; 2010 Feb; 44(2):115-25. PubMed ID: 19850646
[TBL] [Abstract][Full Text] [Related]
37. Involvement of PI3K/Akt signaling pathway in hepatocyte growth factor-induced migration of uveal melanoma cells.
Ye M; Hu D; Tu L; Zhou X; Lu F; Wen B; Wu W; Lin Y; Zhou Z; Qu J
Invest Ophthalmol Vis Sci; 2008 Feb; 49(2):497-504. PubMed ID: 18234991
[TBL] [Abstract][Full Text] [Related]
38. Kringle 1-4 of hepatocyte growth factor inhibits proliferation and migration of human microvascular endothelial cells.
Kuba K; Matsumoto K; Ohnishi K; Shiratsuchi T; Tanaka M; Nakamura T
Biochem Biophys Res Commun; 2000 Dec; 279(3):846-52. PubMed ID: 11162438
[TBL] [Abstract][Full Text] [Related]
39. Anti-c-MET Nanobody - a new potential drug in multiple myeloma treatment.
Slørdahl TS; Denayer T; Moen SH; Standal T; Børset M; Ververken C; Rø TB
Eur J Haematol; 2013 Nov; 91(5):399-410. PubMed ID: 23952536
[TBL] [Abstract][Full Text] [Related]
40. A novel recombinant soluble splice variant of Met is a potent antagonist of the hepatocyte growth factor/scatter factor-Met pathway.
Tiran Z; Oren A; Hermesh C; Rotman G; Levine Z; Amitai H; Handelsman T; Beiman M; Chen A; Landesman-Milo D; Dassa L; Peres Y; Koifman C; Glezer S; Vidal-Finkelstein R; Bahat K; Pergam T; Israel C; Horev J; Tsarfaty I; Ayalon-Soffer M
Clin Cancer Res; 2008 Jul; 14(14):4612-21. PubMed ID: 18628476
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]